Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

Interrelationships between inflammation, C-reactive protein, and insulin resistance.

Ndumele CE, Pradhan AD, Ridker PM.

J Cardiometab Syndr. 2006 Summer;1(3):190-6. Review.

2.

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.

Haffner SM.

Am J Cardiol. 2006 Jan 16;97(2A):3A-11A. Review.

PMID:
16442931
3.

[Clinical significance of high-sensitivity C-reactive protein in lifestyle-related disease and metabolic syndrome].

Yoshikane H, Yamamoto T, Ozaki M, Matsuzaki M.

J Cardiol. 2007 Sep;50(3):175-82. Japanese.

PMID:
17941193
4.

Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study.

Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA.

J Am Coll Cardiol. 2008 May 6;51(18):1775-83. doi: 10.1016/j.jacc.2007.12.048.

6.

Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin.

González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O.

Eur J Clin Nutr. 2006 Jun;60(6):802-9.

PMID:
16493453
7.

Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?

Greenfield JR, Campbell LV.

Curr Diabetes Rev. 2006 May;2(2):195-211. Review.

PMID:
18220627
8.

[High sensitivity of C-reactive protein in primary prevention].

Corrado E, Novo S.

G Ital Cardiol (Rome). 2007 Jun;8(6):327-34. Review. Italian.

PMID:
17633905
9.

[Inflammation and C-reactive protein in cardiovascular disease].

Munk PS, Larsen AI.

Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4. doi: 10.4045/tidsskr.08.0011. Review. Norwegian.

10.

C-reactive protein and metabolic syndrome in youth: a strong relationship?

Oliveira AC, Oliveira AM, Adan LF, Oliveira NF, Silva AM, Ladeia AM.

Obesity (Silver Spring). 2008 May;16(5):1094-8. doi: 10.1038/oby.2008.43. Retraction in: Oliveira AC, Oliveira AM, Adan LF, Oliveira NF, Silva AM, Ladeia AM. Obesity (Silver Spring). 2009 Jun;17(6):1113.

11.

Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.

Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R.

Diabetes Care. 2005 Mar;28(3):690-3.

PMID:
15735209
12.

Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population.

Sung SH, Chuang SY, Sheu WH, Lee WJ, Chou P, Chen CH.

Am J Cardiol. 2009 May 15;103(10):1411-6. doi: 10.1016/j.amjcard.2009.01.355.

PMID:
19427438
13.
14.

Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis.

Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A.

J Rheumatol. 2007 Apr;34(4):681-8.

PMID:
17299845
15.
16.

Pre-diabetes, insulin resistance, inflammation and CVD risk.

Haffner SM.

Diabetes Res Clin Pract. 2003 Jul;61 Suppl 1:S9-S18. Review.

PMID:
12880690
19.

Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients.

Lee SH, Park SA, Ko SH, Yim HW, Ahn YB, Yoon KH, Cha BY, Son HY, Kwon HS.

Metabolism. 2010 Feb;59(2):241-6. doi: 10.1016/j.metabol.2009.07.019.

PMID:
19765773
20.

The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.

Mikhailidis DP, Press M.

Expert Opin Pharmacother. 2007 Dec;8(17):3009-20. Review.

PMID:
18001259

Supplemental Content

Support Center